How many drugs treat Relapse multiple myeloma?

Drug Landscape tracks 5 marketed treatments for Relapse multiple myeloma (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/relapse-multiple-myeloma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Relapse multiple myeloma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Relapse multiple myeloma (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Relapse multiple myeloma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Blenrep	BELANTAMAB MAFODOTIN	GSK		BCMA	2020-01-01
Huluc63	elotuzumab	Bristol-Myers Squibb	SLAMF7-directed Immunostimulatory Antibody [EPC]	SLAM family member 7	2015-01-01
Kyprolis	carfilzomib	Amgen	Proteasome Inhibitor [EPC]	Proteasome subunit beta type-5	2012-01-01
Kyprolis	Kyprolis	Black Sea Hematology Association		Cathepsin B, Glutathione S-transferase omega-1, Proteasome subunit beta type-10
Blenrep	Blenrep	Duke University		Low affinity immunoglobulin gamma Fc region receptor III-A, High affinity immunoglobulin gamma Fc receptor I, IgG receptor FcRn large subunit p51

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Amgen · 1 drug in Relapse multiple myeloma
Black Sea Hematology Association · 1 drug in Relapse multiple myeloma
Bristol-Myers Squibb · 1 drug in Relapse multiple myeloma
Duke University · 1 drug in Relapse multiple myeloma
GSK · 1 drug in Relapse multiple myeloma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Relapse multiple myeloma:

Cite this brief

Drug Landscape (2026). Relapse multiple myeloma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/relapse-multiple-myeloma. Accessed 2026-06-10.

Relapse multiple myeloma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing